Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...
Senseonics VP of Product Development Hari Sree explains the tech behind the Eversense 365-day CGM and what’s next in the ...
The next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a ...
By Karen Roman GlucoTrack, Inc. (Nasdaq: GCTK) said a peer-reviewed study published in the Institute of Electrical and Electronics Engineers Sensors Journal supported the feasibility of long-life ...
GERMANTOWN, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...
GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...
This diabetes technology offers a continuous stream of data to show a more complete picture of your blood sugars over time. This is different from a fingerstick meter that only represents that moment.
Wearable makers like Apple, Samsung, Garmin, and Google have long chased what might be the holy grail of health tech: non-invasive glucose monitoring. Recent developments suggest that Apple could be ...
Please provide your email address to receive an email when new articles are posted on . The Freestyle Libre 2 and 3 CGM sensors are now approved to be worn during imaging procedures. A system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results